Eikon Therapeutics financials
$7.910.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$93.4M | -$87.3M |
| Net income | -$88.4M | -$83.0M |
| Net margin | — | — |
| Diluted EPS | $-1.63 | $-2.46 |
| EBITDA | -$88.3M | -$82.1M |
| Operating cash flow | -$65.0M | -$89.8M |
| Free cash flow | -$65.2M | -$90.1M |
| Diluted shares | 54.1M | 33.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $142.6M | $161.2M |
| Short-term investments | $388.6M | $351.0M |
| Total debt | $0.00 | $0.00 |
| Total assets | $779.6M | $850.8M |
| Total liabilities | $313.1M | $300.2M |
| Shareholders' equity | $466.5M | $550.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology